## **Thomas Held**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4269385/publications.pdf Version: 2024-02-01



THOMAS HELD

#	Article	IF	CITATIONS
1	Retrospective analysis of outcome and toxicity after postoperative radiotherapy in patients with squamous cell carcinoma of the lip. Tumori, 2022, 108, 125-133.	1.1	4
2	Combined DNA Damage Repair Interference and Ion Beam Therapy: Development, Benchmark, and Clinical Implications of a Mechanistic Biological Model. International Journal of Radiation Oncology Biology Physics, 2022, 112, 802-817.	0.8	6
3	SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. Radiotherapy and Oncology, 2022, 168, 106-112.	0.6	10
4	Frequency of osteoradionecrosis of the lower jaw after radiotherapy of oral cancer patients correlated with dosimetric parameters and other risk factors. Head & Face Medicine, 2022, 18, 7.	2.1	6
5	Radiation-induced contrast enhancement following proton radiotherapy for low-grade glioma depends on tumor characteristics and is rarer in children than adults. Radiotherapy and Oncology, 2022, 172, 54-64.	0.6	9
6	Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial. Radiation Oncology, 2022, 17, .	2.7	3
7	Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands. Cancers, 2021, 13, 124.	3.7	1
8	Individualized 3D-Printed Tissue Retraction Devices for Head and Neck Radiotherapy. Frontiers in Oncology, 2021, 11, 628743.	2.8	7
9	3D-printed individualized tooth-borne tissue retraction devices compared to conventional dental splints for head and neck cancer radiotherapy: a randomized controlled trial. Radiation Oncology, 2021, 16, 75.	2.7	5
10	Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study. BMC Cancer, 2021, 21, 812.	2.6	9
11	Treatment delay and tumor size in patients with oral cancer during the first year of the <scp>COVID</scp> â€19 pandemic. Head and Neck, 2021, 43, 3493-3497.	2.0	31
12	Carbon Ion Radiation Therapy: One Decade of Research and Clinical Experience at Heidelberg Ion Beam Therapy Center. International Journal of Radiation Oncology Biology Physics, 2021, 111, 597-609.	0.8	10
13	Effectiveness and Toxicity of Fractionated Proton Beam Radiotherapy for Cranial Nerve Schwannoma Unsuitable for Stereotactic Radiosurgery. Frontiers in Oncology, 2021, 11, 772831.	2.8	5
14	Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience. Radiology and Oncology, 2021, 55, 467-473.	1.7	5
15	Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations. Frontiers in Oncology, 2021, 11, 757031.	2.8	17
16	Screening and Psycho-Oncological Support for Patients With Head and Neck Cancer and Brain Malignancies Before Radiotherapy With Mask Fixation: Results of a Feasibility Study. Frontiers in Psychology, 2021, 12, 760024.	2.1	1
17	The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2020, 106, 167-173.	0.8	18
18	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors. Cancers, 2020, 12, 2862.	3.7	3

THOMAS HELD

#	Article	IF	CITATIONS
19	Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial. Radiation Oncology, 2020, 15, 190.	2.7	10
20	Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. Clinical Lung Cancer, 2020, 22, 332-340.e3.	2.6	11
21	Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiotherapy and Oncology, 2020, 150, 159-163.	0.6	47
22	Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck. Frontiers in Oncology, 2019, 9, 755.	2.8	2
23	Definitive radiotherapy vs. postoperative radiotherapy for lower gingival carcinomas of the mandible. Strahlentherapie Und Onkologie, 2019, 195, 819-829.	2.0	6
24	Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience. Cancers, 2019, 11, 1705.	3.7	25
25	Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 803-811.	0.8	40
26	Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma. Pancreatology, 2019, 19, 963-970.	1.1	3
27	The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience. Oral Oncology, 2019, 97, 115-123.	1.5	10
28	Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control. Cancers, 2019, 11, 379.	3.7	15
29	<p>Carbon-ion radiotherapy in accelerated hypofractionated active raster-scanning technique for malignant lacrimal gland tumors: feasibility and safety</p> . Cancer Management and Research, 2019, Volume 11, 1155-1166.	1.9	15
30	Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer. Cancers, 2019, 11, 383.	3.7	6
31	The role of organ―and functionâ€preserving radiotherapy in the treatment of adenoid cystic carcinoma of the larynx. Head and Neck, 2019, 41, 2208-2214.	2.0	6
32	Results of a combination treatment with intensity modulated radiotherapy and active raster-scanning carbon ion boost for adenoid cystic carcinoma of the minor salivary glands of the nasopharynx. Oral Oncology, 2019, 91, 39-46.	1.5	25
33	Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience. Radiation Oncology, 2019, 14, 34.	2.7	12
34	Dose-Limiting Organs at Risk in Carbon Ion Re-Irradiation of Head and Neck Malignancies: An Individual Risk-Benefit Tradeoff. Cancers, 2019, 11, 2016.	3.7	6
35	Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma. Frontiers in Oncology, 2019, 9, 1420.	2.8	9
36	Rare entities in head-and-neck cancer: salvage re-irradiation with carbon ions. Radiation Oncology, 2019, 14, 202.	2.7	6

THOMAS HELD

#	Article	IF	CITATIONS
37	Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity. Cancers, 2018, 10, 488.	3.7	15
38	Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution's Clinical Experience. Cancers, 2018, 10, 457.	3.7	13
39	Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety. Cancers, 2018, 10, 388.	3.7	7